Agilent said it has uncovered new and relevant facts in its intellectual property lawsuit against Twist and its Founder and CEO Emily LeProust.
The synthesis method will be incorporated into the silicon array the company developed to produce DNA at scale.
In a proof-of-concept study published in Nature Biotechnology this week, the team demonstrated that it could enzymatically synthesize 10-mer oligonucleotides.
The deals cover the company's synthetic DNA and next-generation sequencing products, including its newly launched target enrichment line.
The grant money will be provided through the EC's Horizon 2020 European Innovation Council program and Bpifrance's innovation development programs.
The company, which recently entered the next-generation sequencing sample prep market, said it has raised $259 million since it was founded in 2013.
Twist Bioscience wants to shrink DNA synthesis to smaller and smaller volumes, possibly enabling DNA storage, according to the San Francisco Chronicle.
The company, which was founded in 2016, said it would use the funding to further develop its core gene synthesis platform.
DNA Script has acquired an exclusive license to a novel DNA building block for use in enzymatic DNA synthesis.
Maravai was launched in 2014 by private equity firm GTCR in partnership with two former Gen-Probe executives.
Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.
The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.
Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.
In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.